Format

Send to

Choose Destination
Trends Immunol. 2016 Feb;37(2):141-153. doi: 10.1016/j.it.2015.12.007. Epub 2016 Jan 7.

The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies.

Author information

1
Department of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA.
2
Department of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA; Department of Pathology and Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA. Electronic address: yxfu@bsd.uchicago.edu.

Abstract

Accumulating evidence indicates that the efficacy of tumor-targeted therapies relies on the host immune response, including targeted small-molecule and antibody approaches that were not previously thought to have an immune component. Here, we review the current understanding of how targeted therapies on tumor cells could have a major impact on the immune response, and how this relates to the therapeutic efficacy of these approaches. In this context, we evaluate different strategies that combine targeted therapies with immunotherapy approaches, and discuss past and ongoing clinical trials. We highlight gaps in knowledge, and argue that significant progress for combined therapies will require a better understanding of the complex interactions between immune cells, the tumor, and the tumor microenvironment (TME) in different cancer settings.

PMID:
26778079
PMCID:
PMC4738073
DOI:
10.1016/j.it.2015.12.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center